Aragon clinches $25m in series B
This article was originally published in Clinica
Executive Summary
Palo Alto, California-based surgical device developer Aragon Surgical has closed a $25m series B financing round led by Cay City Capital. Integral Capital Partners, as well as existing investors Delphi Ventures and ONSET Ventures, also participated in the fundraising. Aragon launched its first product, the LapCap pneumoperitoneum creation assist device, in September 2007 and said it has "several additional products in development".
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.